Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry-Reference-Cited by-同舟云学术

Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry

Published:2023-02 Issue:2 Volume:138 Page:106967
ISSN:1096-7192
Container-title:Molecular Genetics and Metabolism
language:en
Short-container-title:Molecular Genetics and Metabolism

Author:

Hopkin Robert J.,Cabrera Gustavo H.,Jefferies John L.,Yang Meng,Ponce Elvira,Brand Eva,Feldt-Rasmussen Ulla,Germain Dominique P.,Guffon Nathalie,Jovanovic Ana,Kantola Ilkka,Karaa Amel,Martins Ana M.,Tøndel Camilla,Wilcox William R.,Yoo Han-Wook,Burlina Alessandro P.,Mauer Michael

Funder

Sanofi

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology,Biochemistry,Endocrinology, Diabetes and Metabolism

Reference74 articles.

1. Fabry disease;Germain;Orphanet J. Rare Dis.,2010

2. Fabry disease revisited: management and treatment recommendations for adult patients;Ortiz;Mol. Genet. Metab.,2018

3. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry;Auray-Blais;Clin. Chim. Acta,2015

4. Biomarkers for diagnosing and staging of Fabry disease;Krämer;Curr. Med. Chem.,2018

5. Fibrosis: a key feature of Fabry disease with potential therapeutic implications;Weidemann;Orphanet J. Rare Dis.,2013

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuropathy and pain in Fabry disease;Rare Disease and Orphan Drugs Journal;2024-07-08

2. Oxidative stress and its role in Fabry disease;Journal of Nephrology;2024-06-15

3. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data;Drug Design, Development and Therapy;2024-04

4. Anderson–Fabry disease management: role of the cardiologist;European Heart Journal;2024-03-15

5. Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients;Clinica Chimica Acta;2024-03